Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Research & Development (2020 - 2025)

Historic Research & Development for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to $3.8 million.

  • Maravai Lifesciences Holdings' Research & Development fell 1828.23% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.2 million, marking a year-over-year decrease of 560.4%. This contributed to the annual value of $19.2 million for FY2024, which is 1123.26% up from last year.
  • As of Q3 2025, Maravai Lifesciences Holdings' Research & Development stood at $3.8 million, which was down 1828.23% from $4.9 million recorded in Q2 2025.
  • Maravai Lifesciences Holdings' 5-year Research & Development high stood at $9.2 million for Q4 2021, and its period low was $1.9 million during Q2 2021.
  • Over the past 5 years, Maravai Lifesciences Holdings' median Research & Development value was $4.6 million (recorded in 2024), while the average stood at $4.4 million.
  • In the last 5 years, Maravai Lifesciences Holdings' Research & Development soared by 33900.57% in 2021 and then crashed by 4543.77% in 2022.
  • Quarter analysis of 5 years shows Maravai Lifesciences Holdings' Research & Development stood at $9.2 million in 2021, then tumbled by 45.44% to $5.0 million in 2022, then fell by 8.32% to $4.6 million in 2023, then fell by 0.72% to $4.6 million in 2024, then fell by 15.72% to $3.8 million in 2025.
  • Its Research & Development was $3.8 million in Q3 2025, compared to $4.9 million in Q2 2025 and $4.9 million in Q1 2025.